title: Regulation of epidermal growth factor receptor activity by crotoxin, a snake venom phospholipase A2 toxin. A novel growth inhibitory mechanism.
abstract: Crotoxin (CT), a phospholipase A2 (PLA2) derived from the venom of Crotalus durissus terrificus, is a heterodimeric protein composed of subunit B with enzymatic activity and a binding regulatory subunit (A) without enzyme activity. Although the PLA2 activity of CT may be important in its anti-proliferative activity, its cytostatic mechanism is unknown. In this study, we examined the cytostatic effect of PLA2-associated CT activity on squamous carcinoma cells expressing distinct levels of epidermal growth factor receptor (EGFr). CT was most effective in suppressing growth on cells expressing high intrinsic levels of EGFr. Cardiotoxin, another membrane active toxin with no intrinsic PLA2 activity, had no differential anti-proliferative activity on cells expressing high EGFr levels, suggesting a correlation between EGFr expression and CT-directed anti-proliferative activity. Both chemically modified CT (MCT) devoid of PLA2 activity and covalently cross-linked CT (CCT), which is functionally unable to utilize cellular membranes as PLA2 substrate, were also without growth inhibitory activity. No evidence for direct binding of CT to EGFr was found, although pretreatment with EGF was able to partially suppress the anti-proliferative activity of CT. Tyrosine phosphorylation of EGFr, however, was stimulated by CT in intact A431 cells. Tyrosine phosphorylation of EGFr was concentration-dependently stimulated (3- to 8-fold) in cellular membranes of A431 cells treated in vitro with CT but not with anti-proliferatively inactive MCT or CCT. The data provide evidence for transmembrane receptors involved in growth signaling (namely EGFr) as cellular targets and potential effectors of PLA2-mediated anti-proliferative activity of snake venom.
authors.affiliation: Department of Clinical Immunology, University of Texas M.D. Anderson Cancer Center, Houston, USA.
authors.forename: N J
authors.initials: NJ
authors.lastname: Donato
authors.forename: C A
authors.initials: CA
authors.lastname: Martin
authors.forename: M
authors.initials: M
authors.lastname: Perez
authors.forename: R A
authors.initials: RA
authors.lastname: Newman
authors.forename: J C
authors.initials: JC
authors.lastname: Vidal
authors.forename: M
authors.initials: M
authors.lastname: Etcheverry
mesh_terms: D000818:Animals; D002455:Cell Division / Q000187:drug effects; D003439:Crotoxin / Q000378:metabolism / Q000494:pharmacology*; D004815:Epidermal Growth Factor / Q000378:metabolism; D066246:ErbB Receptors / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology*; D005260:Female; D006801:Humans; D010741:Phospholipases A / Q000378:metabolism; D054467:Phospholipases A2; D014407:Tumor Cells, Cultured; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000648:ultrastructure
chemical_list: D004815:Epidermal Growth Factor; D003439:Crotoxin; D066246:ErbB Receptors; D010741:Phospholipases A; D054467:Phospholipases A2